Incyte (INCY) Stock Analysis: AI Score & Alternative Data
INCY alt-data: revenue climbing, business outlook lagging
Is Incyte a buy right now? The alternative data says hold. This INCY stock analysis is built on the 25+ alternative data signals AltIndex tracks on Incyte every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 53/100: a Hold. The stock trades at $126.93 with a $25B market cap.
The bullish side of the 90-day ledger: revenue up 36.9% YoY to $1.7B, job postings up 74.0% to 167 open roles, and web traffic up 7.1% to 78K monthly visits. The drag: business outlook fell 9.1% — now 70% of employees are positive. That tension is what keeps the score mid-range.
INCY’s broader alt-data profile also covers headcount (4K employees, according to LinkedIn), X followers (7K), Reddit mentions (1 a day), and sentiment (100/100). Every signal links to its own page with full history, the INCY technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on INCY is just below.
Incyte AI Stock Analysis
Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. With a strategic focus on oncology, Incyte has made significant advancements with products like Jakafi, which is used in treating myelofibrosis and polycythemia vera.
Analysis generated August 1, 2026.
Recent Incyte Stock Alerts
|
Incyte | August 18 Job postings are down by 22.9% in the last couple of days. |
|
Incyte | August 14 Job postings are down by 17.8% in the last couple of days. |
|
Incyte | August 11 Over the past few months, there has been an upward trend in Web Traffic. |
|
Incyte | August 6 Insider Alert: Mayes Patrick A is selling shares |
Incyte Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 78K | 7.1% | |
| Job Posts | 167 | 74.0% | |
| LinkedIn Employees | 4K | 4.0% | |
| Employee Recommend | 77 | 8.3% | |
| Business Outlook | 70 | 9.1% | |
| Sentiment | 100 | 0% | |
| Reddit Mentions | 1 | N/A | |
| X Mentions | 2 | 85.7% | |
| Stocktwits Mentions | 4 | 42.9% | |
| News Mentions | 2 | 50.0% | |
| Stocktwits Subscribers | 6K | 0.8% | |
| 4chan Mentions | 0 | N/A | |
| X Followers | 7K | 0% | |
| Youtube Subscribers | 319 | 2.2% | |
| Facebook Followers | 6K | 1.1% | |
| Facebook Engagement | 225 | 52.0% |
About Incyte (INCY)
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally.
| Price | $126.93 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $25B |
| Year Range | $82 – $130 |
| Dividend Yield | 0% |
| PE Ratio | 15.7 |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Incyte News
View more → |
Incyte Stock: Is Wall Street Bullish or Bearish?August 18 - Biztoc.com |
Incyte Q2 Earnings Call HighlightsJuly 28 - MarketBeat |
|
 |
What To Expect From Incyte’s (INCY) Q2 EarningsJuly 26 - Biztoc.com |
 |
Halozyme and Incyte sign licence agreement for INCA033989 formulationsJuly 21 - Biztoc.com |
 |
What to Expect From Incyte's Q2 2026 Earnings ReportJuly 15 - Biztoc.com |
Incyte Earnings & Financial Performance
View all earnings →Incyte Insider Trading Activity
View all →| CAGNONI PABLO J filed to sell 194,001 shares at $0.0. Aug 12 '26 |
| Mayes Patrick A filed to sell 61,441 shares at $0.0. Aug 5 '26 |
| CAGNONI PABLO J filed to sell 204,804 shares at $0.0. Aug 5 '26 |
| Mayes Patrick A filed to sell 61,441 shares at $0.0. Aug 3 '26 |
| Mayes Patrick A filed to sell 64,060 shares at $0.0. Jul 31 '26 |
Incyte Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Rob Bresnahan |
Jun 2, 25 | Sell | $8K+ |
| Ro Khanna |
Oct 8, 24 | Sell | $8K+ |
| Rohit Khanna |
May 6, 24 | Sell | $8K+ |
| Rohit Khanna |
May 6, 24 | Sell | $8K+ |
| Rohit Khanna |
Apr 5, 24 | Buy | $8K+ |
Stocks Similar to Incyte
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
West Pharmaceutical ServicesWST |
$353.03 1.9% | $24B | 67 |
 |
BioNTechBNTX |
$110.58 19.2% | $23B | 19 |
 |
United TherapeuticsUTHR |
$528.39 2.0% | $22B | 28 |
 |
Guardant HealthGH |
$162.57 1.5% | $22B | 72 |
 |
IlluminaILMN |
$200.65 6.6% | $29B | 51 |
Explore Incyte Data
Frequently Asked Questions: Incyte (INCY)
Incyte has an AltIndex AI Score of 53/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
53/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Incyte (INCY) stock is $126.93 with a market cap of $25B.
As of today, Incyte’s PE (Price to Earnings) ratio is 15.7.
View the latest Incyte insider transactions to see recent buying and selling activity by company executives and directors.
Check the Incyte congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The INCY stock price chart above shows Incyte’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Incyte technical analysis for RSI, moving averages, and more.
See the stocks similar to Incyte section on this page for companies in the same industry ranked by market cap and AI Score.
